CollPlant Biotechnologies (CLGN) Accounts Payables (2017 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Accounts Payables came in at $610000.0 in Q4 2025, down 29.89% YoY from $870000.0 in Q4 2024, and down 1.29% on a QoQ basis from $618000.0 in Q3 2025.
CollPlant Biotechnologies (CLGN) Accounts Payables (2017 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 9 years of Accounts Payables data on file, last reported at $610000.0 in Q4 2025.
- Quarterly Accounts Payables fell 29.89% year-over-year to $610000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $610000.0 (down 29.89% YoY) and the FY2025 annual result came in at $610000.0, down 29.89% from the prior year.
- Accounts Payables fell to $610000.0 in Q4 2025, from $618000.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $1.1 million in Q2 2024 to a low of $571000.0 in Q2 2025.
- A 5-year average of $872315.8 and a median of $880000.0 in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2024 — Accounts Payables soared 49.15% — and 2025, when it sank 49.82%.
- Tracing CLGN's Accounts Payables over 5 years: stood at $1.0 million in 2021, then increased by 9.57% to $1.1 million in 2022, then declined by 13.5% to $980000.0 in 2023, then dropped by 11.22% to $870000.0 in 2024, then dropped by 29.89% to $610000.0 in 2025.
- The last three Accounts Payables figures came in at $610000.0 (Q4 2025), $618000.0 (Q3 2025), and $571000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 35.57 Mn |
| 10 | CollPlant Biotechnologies | 4.26 Mn | 4.26 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 610,000.00 |
| Sep 30, 2025 | 618,000.00 |
| Jun 30, 2025 | 571,000.00 |
| Dec 31, 2024 | 870,000.00 |
| Sep 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 1.12 Mn |
| Dec 31, 2023 | 980,000.00 |
| Sep 30, 2023 | 744,000.00 |
| Jun 30, 2023 | 763,000.00 |
| Mar 31, 2023 | 885,000.00 |
| Dec 31, 2022 | 1.13 Mn |
| Sep 30, 2022 | 880,000.00 |
| Jun 30, 2022 | 760,000.00 |
| Mar 31, 2022 | 1.00 Mn |
| Dec 31, 2021 | 1.03 Mn |
| Sep 30, 2021 | 865,000.00 |
| Jun 30, 2021 | 698,000.00 |
| Mar 31, 2021 | 894,000.00 |
| Dec 31, 2020 | 798,000.00 |